Administrative Supplement for Upgrading the University of Pittsburgh Regional Biocontainment Laboratory within The Center for Vaccine Research

升级匹兹堡大学疫苗研究中心区域生物防护实验室的行政补充

• 批准号: 10631339
• 负责人: William Paul Duprex
• 金额: $ 332.97万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-08-22 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10631339
• 关键词: Acceleration; Achievement; Address; Administrative Supplement; Aging; Animals; Applications Grants; Award; Biological; Biology; COVID-19 pandemic; Capital; Categories; Cells; Cities; Communities; Confocal Microscopy; Contractor; Diagnostic; Discipline; Ecosystem; Elements; Emerging Communicable Diseases; Ensure; Equipment; Evolution; Ferrets; Four-dimensional; Funding; Goals; Health; Human; Hydrogen Peroxide; Immunologics; In Vitro; Infection; Infectious Agent; Infectious Diseases Research; Infrastructure; Institution; Intervention; Knowledge; Laboratories; Leadership; Molecular; National Institute of Allergy and Infectious Disease; Oryctolagus cuniculus; PET/CT scan; Paper; Parents; Pathogenesis; Pathologic; Pennsylvania; Persons; Public Health; Publications; Recording of previous events; Research; Research Infrastructure; Research Personnel; Resources; Rodent; Structural Biologist; Therapeutic antibodies; Time; Tissues; Toxin; Training; Translating; Translational Research; United States National Institutes of Health; Universities; Vaccine Research; Vaccines; Viral; Virus; Vision; Work; biodefense; bioimaging; cohort; cost effective; experience; faculty research; flexibility; in vivo imaging system; medical schools; multimodality; nanobodies; novel; operation; pandemic disease; pandemic preparedness; parent project; pathogen; preclinical development; priority pathogen; programs; recruit; response; small molecule inhibitor; success; vapor

ABSTRACT: The Center for Vaccine Research (CVR) investigators conduct research on BSL-3 Category A, B, and C priority pathogens that have an impact on the health of people around the world. This is facilitated by the integral NIAID supported Regional Biocontainment Laboratory (RBL) which provides biosafety level (BSL)-2 and animal (A)BSL-3 capabilities. CVR is the hub for infection biology at the University of Pittsburgh bringing together virologists, bacteriologists, biochemists, structural biologists and clinicians from a variety of disciplines who have a common goal of investigating the evolution and pathogenesis of emerging infectious diseases and biodefense pathogens. The center enables the acceleration of pre-clinical development of novel interventions such as vaccines, therapeutic antibodies and nanobodies, small molecule inhibitors and diagnostics for viruses and other infectious agents. In 2021 CVR received a $3.3 million award to support fixed and non-fixed equipment upgrades within the RBL (G20AI167405). In this supplement to the parent, we focus on addressing scientific deficits and concentrate on the lack of flexible ABSL-3 space, small animal bioimaging capabilities and revitalizing core, shared equipment. Multimodal bioimaging capabilities are integral elements in understanding how pathogens infect cells, tissues and animals in four-dimensions. In this supplement we will expand our bioimaging capabilities to small and medium sized animals to augment our active large animal programs. These upgrades will be integrated into the current G20 parent project making it very cost effective in terms of recommissioning the facility. This ensure the supplement is fully within the scope of the parental award. This will ensure the University of Pittsburgh RBL remains fit-for-purpose and emerging infectious disease response-ready for another fifteen years. The facility is considered essential research infrastructure by the University of Pittsburgh, for the region, the state and nation. CVR staff have made major contributions to the ongoing COVID-19 pandemic by leveraging their significant experience working on pathogens with pandemic potential in biocontainment. Maintaining well trained, response ready cohorts of infection biologists across nation is vitally important as pathogens will continue to emerge. This makes pandemic preparedness an essential element of the national research portfolio.

摘要： 疫苗研究中心（CVR）研究人员对BSL-3 A、B和C类优先级进行研究 对全世界人民的健康产生影响的病原体。这是由一体化NIAID促进的 支持区域生物防护实验室（RBL），提供生物安全等级（BSL）-2和动物 （A）BSL-3能力。CVR是匹兹堡大学感染生物学的中心，汇集了 来自不同学科的病毒学家、细菌学家、生物化学家、结构生物学家和临床医生， 一个共同的目标是调查新出现的传染病和生物防御的演变和发病机制 病原体该中心能够加速新型干预措施的临床前开发， 疫苗、治疗性抗体和纳米抗体、小分子抑制剂和病毒及其他疾病的诊断 传染源2021年，CVR获得了330万美元的奖励，用于支持固定和非固定设备升级 在RBL（G20 AI 167405）内。在这篇对父母的补充中，我们专注于解决科学缺陷， 专注于缺乏灵活的ABSL-3空间，小动物生物成像能力和振兴核心， 共享设备。多模态生物成像能力是理解病原体如何 在四维空间中感染细胞、组织和动物。在本补充中，我们将扩大我们的生物成像 能力，以小型和中型动物，以加强我们积极的大型动物计划。这些升级 将被整合到当前的G20母项目中，使其在重新调试方面具有非常高的成本效益 设施。这确保了补贴完全在父母奖励的范围内。这将确保 匹兹堡大学RBL仍然适合目的和新出现的传染病反应准备另一个 十五年该设施被匹兹堡大学认为是必不可少的研究基础设施， 地区、国家和民族。CVR员工为持续的COVID-19疫情做出了重大贡献， 利用他们在生物遏制方面对具有大流行潜力的病原体进行研究的丰富经验。 在全国范围内保持训练有素、随时准备应对的感染生物学家群体至关重要， 病原体将继续出现。这使得大流行病的防范成为国家预防和控制的一个基本要素。 研究组合。